

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




FIG. 1A.




FIG. 1B.




FIG. 1C.




FIG. 2.




FIG. 3A.

Cyclin A ▶




FIG. 3B.




FIG. 3C.




FIG. 4A.




FIG. 4B.




FIG. 4C.




FIG. 4D.

Title: Method of Treating Cancer Using
Dithiocarbamate Derivatives
Inventor(s): Thomas P. Kennedy
Application No. To Be Assigned
Atty Dkt No: 046428/275157




FIG. 5A.




FIG. 5B.

DMSO
G0-G1: 59.92
G2-M: 5.43
S-Phase: 34.65




FIG. 6A.

Disulfiram
G0-G1: 54.97
G2-M: 3.64
S-Phase: 41.39




FIG. 6B.

Disulfiram + Ceruloplasmin

G0-G1: 32.82

G2-M: 0.00

S-Phase: 67.18, Apoptosis: 6.13%




FIG. 6C.




FIG. 7A.




FIG. 7B.




FIG. 7C.




FIG. 7D.




FIG. 8.